Sort
34,240 grants matching “atherosclerosis”
CETP and HDL Function in Cardiovascular Diseases
$607,612Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2014 · HL
Microbial Disruption of Dendritic Cell Maturation and Function
$607,603Caroline A Genco · Tufts University Boston · R01 · FY2018 · AI
Genomewide Association Study of Statin Response and its Consequences
$607,599Neil J Risch · Children'S Hospital & Res Ctr At Oakland · P50 · FY2019 · GM
Physician Scientist Training in Age-Related Diseases
$607,576Lona Mody · University Of Michigan At Ann Arbor · T32 · FY2023 · AG
PIK3C3, a master regulator for smooth muscle identity
$607,543Jiliang Zhou · Augusta University · R01 · FY2024 · HL
Nanoparticles for Molecular MRI of Atherosclerosis
$607,523Zahi A. Fayad · Icahn School Of Medicine At Mount Sinai · R01 · FY2007 · HL
Therapeutic Approaches to Dysregulated HDL Metabolism
$607,496Henry J. Pownall · Baylor College Of Medicine · R01 · FY2009 · HL
Coronary artery dysfunction in OSA: Role of mineralocorticoid receptors
$607,475Mohammad Badran · University Of Missouri-Columbia · R01 · FY2024 · HL
Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis
$607,392Babak Razani · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL
A Neurobehavioral Family Study of Schizophrenia
$607,282University Of Pittsburgh At Pittsburgh · R01 · FY2003 · MH
Endothelial cell- specific Wnt suppression ameliorates vascular inflammation
$607,228Julie Goodwin · Yale University · R01 · FY2024 · HL
WEIBEL PALADE BODY FORMATION AND ROLE IN HEMOSTASIS
$607,062Immune Disease Institute, Inc. · R37 · FY2003 · HL
RISK FACTORS FOR CV DISEASE IN A DIALYSIS COHORT
$606,961Johns Hopkins University · R01 · FY2003 · HL
Metabolic control in vascular remodeling
$606,879Nicholas E Sibinga · Albert Einstein College Of Medicine · R01 · FY2020 · HL
The Role Of Nrf2 In Susceptibility To Hyperoxic Lung Injury
$606,752Steven R Kleeberger · National Institute Of Environmental Health Sciences · ZIA · FY2013 · ES
A Novel Approach to Examine Within-Class Therapeutic Exchangeability of Medications
$606,674Tobias Gerhard · Rutgers Biomedical/Health Sciences-Rbhs · R01 · FY2021 · AG
Integrative genomic, transcriptomic and proteomic studies of pulmonary function and COPD
$606,652Ani Wang Manichaikul · University Of Virginia · R01 · FY2024 · HL
Profiling splicing isoforms in single cells in the atherosclerosis niche
$606,564Myriam Gorospe · National Institute On Aging · ZIA · FY2023 · AG
Development of a Porcine Model of Atherosclerosis
$606,442Christopher Rogers · Exemplar Genetics, Llc · R44 · FY2012 · HL
Microbiota-focused strategies to mitigate GVHD
$606,287Robert Jenq · Sloan-Kettering Inst Can Research · R01 · FY2015 · HL
Biomarkers and mechanisms of metal and mixed metal exposures
$606,251Laurie G Hudson · University Of New Mexico Health Scis Ctr · P42 · FY2025 · ES
Behavioral Economic Approaches to Increase Physical Activity among Patients with Elevated Risk for Cardiovascular Disease
$606,149Mitesh S. Patel · University Of Pennsylvania · R33 · FY2019 · HL
Lipid transport, oxidation and toxicity in the retina
$606,134Ignacio R Rodriguez · National Eye Institute · ZIA · FY2014 · EY
Epidemiology of blood pressure responses to perturbations: Correlates and prognosis for vascular risk, end-organ damage, cognitive aging and preclinical Alzheimer's disease
$606,121Vasan S. Ramachandran · University Of Texas Hlth Science Center · R01 · FY2025 · AG
Progression of Cardiovascular Disease in Lupus.
$606,105Susan Manzi · University Of Pittsburgh At Pittsburgh · R01 · FY2008 · AR